DNA X, Inc.

For the period ended Mar 31, 2026. Filed May 20, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 20, 2026

SONM$2.35+5.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Deficit

(IN THOUSANDS EXCEPT SHARE AMOUNTS)

Common stock · Additional Paid-in · Accumulated · Stockholders’
For the Three Months Ended March 31, 2025	Shares (*)	Amount (*)	Capital (*)	Deficit	Deficit
Balance at January 1, 2025	276,881	$—	$277,908	$(283,608)	$(5,700)
Issuance of common stock upon exercise of stock options and settlement of restricted stock units, net of taxes withheld	117	—	—	—	—
Issuance of common stock, net of issuance costs	74,859	1	3,536	—	3,537
Stock-based compensation	—	—	626	—	626
Net income	—	—	—	458	458
Balance at March 31, 2025	351,857	$1	$282,070	$(283,150)	$(1,079)

Common stock · Additional Paid-in · Accumulated · Stockholders’
For the Three Months Ended March 31, 2026	Shares (*)	Amount (*)	Capital (*)	Deficit	Deficit
Balance at January 1, 2026	1,265,067	$1	$296,309	$(304,265)	$(7,955)
Remeasurement of redemption value of redeemable common stock	—	—	—	328	328
Stock-based compensation	—	—	304	—	304
Net income	—	—	—	6,340	6,340
Balance at March 31, 2026	1,265,067	$1	$296,613	$(297,597)	$(983)

(*)	Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 27, 2025, see Note 1.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.